Free Trial

I-Mab (IMAB) Competitors

I-Mab logo
$2.12 +0.01 (+0.47%)
Closing price 04:00 PM Eastern
Extended Trading
$2.10 -0.02 (-0.71%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

IMAB vs. MAZE, MRVI, IOVA, URGN, TLRY, TNGX, STOK, PRME, DNTH, and PHAT

Should you be buying I-Mab stock or one of its competitors? The main competitors of I-Mab include Maze Therapeutics (MAZE), Maravai LifeSciences (MRVI), Iovance Biotherapeutics (IOVA), Urogen Pharma (URGN), Tilray Brands (TLRY), Tango Therapeutics (TNGX), Stoke Therapeutics (STOK), Prime Medicine (PRME), Dianthus Therapeutics (DNTH), and Phathom Pharmaceuticals (PHAT). These companies are all part of the "pharmaceutical products" industry.

I-Mab vs. Its Competitors

Maze Therapeutics (NASDAQ:MAZE) and I-Mab (NASDAQ:IMAB) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, analyst recommendations, valuation, earnings, institutional ownership, profitability, media sentiment and dividends.

Maze Therapeutics' return on equity of 0.00% beat I-Mab's return on equity.

Company Net Margins Return on Equity Return on Assets
Maze TherapeuticsN/A N/A N/A
I-Mab N/A -19.81%-18.63%

In the previous week, Maze Therapeutics had 6 more articles in the media than I-Mab. MarketBeat recorded 8 mentions for Maze Therapeutics and 2 mentions for I-Mab. Maze Therapeutics' average media sentiment score of 0.38 beat I-Mab's score of 0.15 indicating that Maze Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Maze Therapeutics
1 Very Positive mention(s)
2 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
I-Mab
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

Maze Therapeutics has higher revenue and earnings than I-Mab.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Maze Therapeutics$167.50M4.30$52.23MN/AN/A
I-Mab$3.89M44.50-$22.23MN/AN/A

38.4% of I-Mab shares are held by institutional investors. 22.1% of I-Mab shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Maze Therapeutics presently has a consensus target price of $25.60, suggesting a potential upside of 55.62%. I-Mab has a consensus target price of $6.00, suggesting a potential upside of 183.02%. Given I-Mab's stronger consensus rating and higher possible upside, analysts clearly believe I-Mab is more favorable than Maze Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Maze Therapeutics
0 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
2 Strong Buy rating(s)
3.29
I-Mab
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
1 Strong Buy rating(s)
3.33

Summary

Maze Therapeutics beats I-Mab on 8 of the 13 factors compared between the two stocks.

Get I-Mab News Delivered to You Automatically

Sign up to receive the latest news and ratings for IMAB and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IMAB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

IMAB vs. The Competition

MetricI-MabMED IndustryMedical SectorNASDAQ Exchange
Market Cap$173.12M$3.05B$5.67B$9.49B
Dividend YieldN/A2.44%4.05%4.00%
P/E RatioN/A20.8627.9419.96
Price / Sales44.50246.07396.5882.69
Price / CashN/A41.9636.1958.45
Price / Book0.868.308.635.82
Net Income-$22.23M-$55.19M$3.24B$258.42M
7 Day Performance-1.85%5.06%3.22%1.94%
1 Month Performance-10.55%17.59%10.71%12.02%
1 Year Performance50.35%7.02%34.94%20.81%

I-Mab Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
IMAB
I-Mab
2.7376 of 5 stars
$2.12
+0.5%
$6.00
+183.0%
+47.6%$173.12M$3.89M0.00380Gap Down
MAZE
Maze Therapeutics
N/A$15.74
+4.6%
$23.50
+49.3%
N/A$689.41M$167.50M0.00121News Coverage
Analyst Forecast
MRVI
Maravai LifeSciences
3.6352 of 5 stars
$2.67
-2.2%
$6.64
+148.6%
-68.6%$679.94M$259.18M-2.34610Options Volume
IOVA
Iovance Biotherapeutics
4.6082 of 5 stars
$2.01
+7.5%
$12.22
+508.1%
-54.3%$671.20M$164.07M-1.62500Analyst Forecast
Options Volume
Gap Down
High Trading Volume
URGN
Urogen Pharma
4.4833 of 5 stars
$14.49
+1.8%
$32.86
+126.8%
+10.2%$668.13M$90.40M-4.56200
TLRY
Tilray Brands
1.8877 of 5 stars
$0.66
+13.1%
$1.92
+191.8%
-61.1%$661.07M$788.94M-0.632,650Upcoming Earnings
Options Volume
TNGX
Tango Therapeutics
1.3436 of 5 stars
$6.09
+2.7%
$12.20
+100.3%
-29.4%$660.12M$40.99M-4.9990
STOK
Stoke Therapeutics
4.2499 of 5 stars
$12.06
+1.7%
$24.75
+105.2%
-2.1%$658.48M$36.56M15.27100
PRME
Prime Medicine
3.9766 of 5 stars
$4.80
+10.3%
$10.08
+110.1%
-19.9%$645.57M$3.85M-2.34234High Trading Volume
DNTH
Dianthus Therapeutics
0.9186 of 5 stars
$20.03
-0.1%
$53.00
+164.6%
-21.0%$644.17M$6.24M-6.9580
PHAT
Phathom Pharmaceuticals
4.3723 of 5 stars
$9.06
-1.3%
$17.50
+93.2%
-29.3%$632.48M$55.25M-1.73110

Related Companies and Tools


This page (NASDAQ:IMAB) was last updated on 7/24/2025 by MarketBeat.com Staff
From Our Partners